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To the Editor: We read with interest the report by van 
der Linden et al. about the prevalence of azole-resistant 
Aspergillus fumigatus isolates from 19 countries, includ-
ing 2 from the Americas (Brazil and the United States) 
(1). Recent reports have suggested a link between use of 
fungicides in agricultural practices and the presence of 
triazole-resistant A. fumigatus among azole-naive persons 
(2). These resistant strains harbored the TR34/L98H and 
TR46/Y121F/T289A mutations in the CYP51A gene and 
its promoter region. These novel mechanisms of resistance 
have been reported both in environmental and clinical sam-
ples in Europe, Asia, and Africa, suggesting a broad geo-
graphic spread. However, clinical isolates from 22 states in 
the United States (3) and a few isolates from Latin America 
(1,4) failed to show any fungicide-driven resistance in A. 
fumigatus in these continents, even though use of pesticides 
is a widespread practice in the Americas. Colombia was 
ranked fourth in the world in 2010 for the use of pesticides, 
reportedly using 14.5 tons/1,000 ha, 30% of which were 
fungicides (5). Among the fungicides approved by Colom-
bia’s regulatory agency, the Colombian Agricultural Insti-
tute (6), tebuconazole and difenoconazole are largely used 
in the flower industry, more specifically in Cundinamarca, 
where 60% of Colombia’s flowers are produced.
In 2015, we conducted a study for which 60 soil sam-
ples from flower fields and greenhouses were collected 
in the outskirts of Bogota, Cundinamarca. Samples were 
inoculated on Sabouraud agar at 43°C, and positive samples 
were screened for azole-resistance on agar supplemented 
with either itraconazole (4 mg/L) or voriconazole (4 mg/L). 
Of the 38 resistant Aspergillus strains, 20 were selected 
(up to 5 colonies for each positive culture), identified as 
A. fumigatus by β-tubulin gene sequencing, and analyzed 
for CYP51A gene alterations (7). Results showed great di-
versity in molecular resistance with the presence of TR46/
Y121F/T289A (n = 17), TR34/L98H (n = 1), and TR53 (n = 
1) mutations; 1 isolate had a wild-type CYP51 sequence (8).
Our study highlights the presence of A. fumigatus har-
boring fungicide-driven alterations in Colombia, South 
America. The results indicate the importance of initiating 
active agricultural surveillance along with close monitor-
ing of drug resistance in clinical isolates from naive and 
azole-exposed patients in these countries. Clinical manage-
ment of Aspergillus disease can be challenging because of 
unfavorable clinical outcomes after patients have acquired 
multi-azole–resistant strains from the environment (9). Ad-
ditional studies are needed to evaluate the extent to which 
pesticide use in floriculture and agriculture (e.g., coffee and 
banana) contributes to azole resistance in Colombia.
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To the Editor: First-line antifungal therapy for inva-
sive aspergillosis (IA) is voriconazole, which is challenged 
by the emergence of azole resistance (1). A recent article 
reported a 3.2% prevalence of Aspergillus fumigatus iso-
lates that are resistant to azole from 3,788 isolates screened 
in Europe (2). Of the 1,911 patients from whom the isolates 
were collected, IA developed in 10 (3 proven, 1 probable, 6 
possible). Prevalence of azole-resistant A. fumigatus disease 
among patient populations at risk of IA was unavailable.
As described (3), we screened every A. fumigatus iso-
late recovered from respiratory specimens from patients 
with probable or proven IA in our hospital in Paris, France, 
during January 2012–December 2014. Every isolate recov-
ered from 2% malt extract agar plates or Sabouraud dex-
trose agar slants (Bio-Rad, Marnes-la-Coquette, France) 
was incubated at 30°C and tested as individual isolates or 
multiple ones from a single sample by using itraconazole, 
voriconazole, and posaconazole Etest strips (bioMérieux, 
Marcy l’Etoile, France). Resistance was assessed for MICs 
>2.0 µg/µL for voriconazole and itraconazole and >0.25 µg/
µL for posaconazole by using European Committee on An-
timicrobial Susceptibility Testing clinical breakpoints for 
fungi (http://www.eucast.org/fileadmin/src/media/PDFs/
EUCAST_files/AFST/Antifungal_breakpoints_v_7.0.pdf).
Every 4 months, a local multidisciplinary medical 
team classified each IA case by using the 2008 criteria es-
tablished by the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections Coopera-
tive Group and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group (4). For 148 patients 
(127 with hematologic malignancies and 21 with other 
conditions), the team recorded 152 episodes: 9 proven 
and 143 probable IA episodes. Possible IA was not ana-
lyzed because of a lack of microbiologic criteria. For 51 
probable IA episodes, galactomannan positivity in blood 
or bronchoalveolar lavage fluid samples was the only mi-
crobiologic criterion used for classification. Cultures of 
respiratory samples (i.e., bronchoalveolar lavage fluid, tra-
cheal aspirate, and sputum) or biopsies were positive for 99 
episodes: 68 with A. fumigatus isolates and 31 with other 
Aspergillus spp. isolates. Among the 68 A. fumigatus iso-
lates, 1 (1.5%) associated with probable IA was resistant to 
azoles (5). The isolate harbored the TR34/L98H mutation 
(5), leading to a rate of IA caused by azole-resistant A. fu-
migatus of 0.7% (1/152) for total episodes recorded and 1% 
(1/99) for culture-positive episodes only. Nineteen (36%) 
of 53 culture-negative patients and 35 (37%) of 95 culture-
positive patients died.
Azole resistance of A. fumigatus warrants specific 
surveillance in hospitals treating immunocompromised pa-
tients. Prevalence of resistant isolates can differ by hospital 
location and underlying disease (e.g., immunodeficiency 
vs. chronic lung diseases). When focusing on patients with 
probable or proven IA, we did not observe an emergence of 
azole-resistant A. fumigatus isolates during 2006–2009 (3) 
and 2012–2014 in France. Consequently, our center does 
not question the use of voriconazole as first-line treatment 
or of posaconazole as prophylaxis.
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